Daxxify (Daxibotulinumtoxin-A)

In short: Daxxify is an FDA-approved Botulinum toxin type A product developed by Revance Therapeutics, containing RTP-004 peptide stabilizer. The longest-acting botulin toxin on the market with a duration of action of up to 6 months; It is not yet available in Türkiye, but is attractive to patients traveling abroad.

Description and Product Features

Daxxify (daxibotulinumtoxin-A) is an injection product containing Botulinum toxin type A (BoNT-A), developed by the US biotechnology company Revance Therapeutics and approved by the FDA for a cosmetic indication on September 9, 2022. It is commercially available in 50 Unit and 100 Unit vials. Daxxify's key differentiator is the integration of peptide stabilizer technology called RTP-004 into the product. This peptide excipient keeps the protein structures balanced and stable, thus extending the shelf life of the product and extending its duration of action. Notably, Daxxify does not contain Human Serum Albumin (HSA); This is the main argument for animal protein-free positioning and provides a reduced risk of allergy for some patients.

The most critical clinical advantage of Daxxify is that its duration of action is significantly longer than Botox (3-4 months) and Dysport (3-4 months). In clinical studies, the median duration of effect of Daxxify was 6.0 months; In fact, in more than 40% of some patients, the effect has been observed to exceed 8-9 months. This long duration of action reduces the patient's injection frequency and improves the quality of life (injection-onset anxiety, calendar planning) in dermatology and aesthetic surgery practice.

Active Ingredient and Formulation

The active ingredient of Daxxify is daxibotulinumtoxin-A; It is a protein molecule with the structure of Botulinum toxin type A lysine residue (BoNT/A-LSNARE). Its molecular weight is approximately 150 kDa (150 kilodaltons) and targets SNARE complex proteins at nerve endings. Daxxify's formulation comes in freeze-dried powder form, like Botox and Dysport; Sterile saline (0.9% NaCl) or sterile water is used for dilution.

RTP-004 Peptide Excipient Technology: The backbone of Daxxify's formulation is a synthetic peptide stabilizer called RTP-004. This peptide creates a protective "shell" around the Botulinum toxin molecule, increasing the stability of the protein structure and reducing the risk of complex protein precipitation and antibody development. RTP-004 is not of animal origin (produced by recombinant DNA technology) and does not contain animal serum albumin like HSA. This feature keeps the risk of histamine-mediated hypersensitivity reactions at a minimum level.

Dose Equivalence: In clinical practice, Daxxify shows 1:1 unitary equivalence with Botox. So, the standard dose of 20 Units of Botox for glabellar wrinkles can be fulfilled with 20 Units of Daxxify. This allows physicians to easily switch from other botulin products (Dysport 1:2.5 ratio) to Daxxify.

Mechanism of Effect

Daxxify, like other botulin toxin preparations, prevents muscle contraction by blocking the release of acetylcholine at nerve endings (neuromuscular junction). The molecular mechanism follows the following steps:

1. Binding: Daxxify's heavy chain (HC, heavy chain) binds to the synapse terminal of the motor neuron of the target muscle. Specifically, it binds to polysialoyl receptors and protein receptor types.
2. Intake (Internalization): The receptor-ligand complex is recruited to the synapse via receptor-mediated endocytosis. RTP-004 peptide provides stabilization of botox at this stage and protects from endosomal pH changes.
3. Chain Translocation: The light chain (LC, light chain) of botoxin passes into the cytoplasm by creating an ionic channel in the endosomal membrane. RTP-004 stabilizes this critical transition.
4. SNARE Cleavage: The endopeptidase activity of the light chain of botoxin cleaves and degrades the SNAP-25 protein, which is a component of the SNARE complex. Knockdown of SNAP-25 prevents the acetylcholine-containing synapic vesicle from docking at the presynaptic membrane.
5. Block Persistence: Anatomically, the complete renewal of SNAP-25 protein (protein turnover) takes 3-6 months. In Daxxify, the stabilizing effect of RTP-004 extends this period, exceeding the median of 6 months.

As a result, target muscle contraction is blocked temporarily (4-9 months), facial wrinkles and dynamic lines are softened, and skin pressure due to muscle relaxation is reduced.

Indications

FDA Approved Indication (2022): Daxxify is approved by the FDA for cosmetic indication only:

• Treatment of dynamic wrinkles in the glabellar region (between the eyebrows) — Adults 18+ years old

Off-Label Uses (Abroad): Like other Botulinum toxin preparations, Daxxify is used off-label in overseas clinics in the following regions:

• Crow's feet (lateral canthal lines)
• Forehead (frontal) lines
• Masseter hypertrophy (chin corner reduction, V-line contouring)
• Bunny lines (lateral surface of the nose)
• Gummy smile (excessive gum exposure)
• Brow lift — frontal and depressor balance
• Nefertiti lift (platysma bands)
• Lip flip (lip edge)

Dosing and Application Technique

Standard Glabellar Dose: The standard dosage of Daxxify for glabellar application is equivalent to Botox:

• For women: 20-25 Units (total)
• In men: 40-50 Units (total) — due to denser muscle mass

5-Point Glabellar Protocol (Carruthers Technique):

1. Central glabellar (midline, 1 cm above supraorbital notch): 4-5 U
2. Left medial corrugator: 8-12 U
3. Right medial corrugator: 8-12 U
4. Left lateral glabellar/procerus: 2-4 U
5. Right lateral glabellar/procerus: 2-4 U

Dilution Protocol: The Daxxify 50U vial is typically reconstituted with 1.0-1.25 mL of sterile saline. This gives a concentration of 40-50 μL/U per unit. The physician can adjust the dilution concentration according to personal application technique (for example, more diluted if he wants wider diffusion, more concentrated if he wants more local).

Injection Technique: Daxxify injection is given intramuscularly (into the muscle). Before injection, the application area is cleaned with antiseptic solution; For patients sensitive to pain, topical anesthetic cream (lidocaine, emla) can be applied for 10-15 minutes. Daxxify needles are 30-32 G (very thin) and most patients report minimal discomfort. The area can be gently massaged after the injection, but heavy massage and lying down are recommended for the first 4 hours (to reduce the spread of the toxin outside the target).

Duration of Effect and Commitment

Onset of Effect: One of the biggest clinical advantages of Daxxify is its rapid onset of action. In 50% of patients, the effect is determined within 24 hours; Observable improvement was found in 85% of patients within 3-5 days. This demonstrates the rapidity advantage of Daxxify compared to the effect profile of Botox (3-7 days) and Dysport (2-4 days).

Full Effect Duration: Daxxify's effect intensity reaches its peak within 2-3 weeks and remains stable for an average of 4-6 months. However, the main difference of Daxxify is that the duration of this effect exceeds 6-7 months on average. In clinical studies (2019-2021 RHA3 and RHA4 trials):

• Median duration of effect: 6.0 months (Botox: 3.8-4.0 months)
• Effect duration of 25% patients: 8+ months
• Effect duration of 40% patients: 7+ months
• Effect fade timeline: It starts to decrease gradually after 5-7 months

Retreatment Interval: The standard protocol is 6 months retreatment on Daxxify. However, in patients with a long duration of effect (7-9 months), the interval between two treatments may be up to 9 months. This reduces patients requiring Botox to one session per year, providing an advantage to the patient in terms of injection-related anxiety, time and cost.

The "Commitment" Phenomenon: Because of Daxxify's long duration of action, some patients may "feel hooked" — that is, they must wait 6-9 months until results appear. This may be a disadvantage for patients who prefer rapid effect fade (who want to trigger again at 3 months). However, most patients prefer the advantage of reducing the frequency of injections.

Antibody and Resistance Development

Protection Against Immunogenicity: Daxxify's RTP-004 peptide technology was developed to reduce immunogenicity. Neutralizing antibodies (NABs) that develop against botulinum toxin products may appear after repeated injections and cause the patient to become unresponsive to botox (botox resistance, secondary non-response). In Daxxify, the RTP-004 stabilizer keeps the protein structure more stable and the exposure of antigenic epitopes is reduced.

Clinical Data: In published studies (Solish et al., 2022), the risk of antibody development with Daxxify was found to be significantly lower than Botox. In particular, HA-free formulation (no human albumin) and peptide excipient technology improve the immunogenicity profile. However, for patients with a very long duration of effect, the risk of antibodies may increase cumulatively when "adherence" exceeds 9 months.

Options in Case of Botox Resistance: If antibodies to Daxxify develop, physicians may consider these options:

• Switching to Dysport (different BoNT/A strain, less cross-reactivity)
• Switch to Xeomin (pure toxin, no complex protein)
• Switching to Jeuveau (new product, antibody repertoire may be different)
• Surgical myectomy/neurectomy (permanent solution)

Side Effects and Contraindications

Local Side Effects (Common, Mild): Daxxify's side effect profile is similar to Botox and Dysport and is mild:

• Mild redness at the injection point (30-40%) — several hours
• Ecchymosis / hematoma (10-15%) — resolves in 3-7 days
• Headache (5-10%) — mild, transient
• Temporary pain or induration at the injection point—24-48 hours

More Rare Side Effects:

• ptosis (droopy eyelid) — 1-2%, after incorrect injection localization; 2-3 weeks autoresorptive
• eyebrow asymmetry — 2-5%, corrected by reinjection
• "Spock brow" — excessive lateral eyebrow elevation; Fixed with touch-up
• droopy corner of the mouth — rare with masseter or perioral administration

Daxxify-Specific Side Effect — Peptide Hypersensitivity: RTP-004 peptide excipient may carry a theoretical risk of IgE-mediated hypersensitivity reaction (allergy). However, in clinical studies (RHA3/RHA4 trials), the number of reported cases of serious allergic reactions is very limited (<0.1%). Mild urticaria (hives) or transitional angioedema have been reported rarely. Since it is an HSA-free formulation, the risk of ovalbumin (egg protein) allergy is less than Botox.

Contraindications: Daxxify is not applied or applied with caution:

• Pregnancy and breastfeeding (Category C) — lack of maternal-fetal toxin transfer data
• Neuromuscular diseases: Myasthenia gravis, Lambert-Eaton syndrome, ALS — toxin effect may be increased
• History of allergy to RTP-004 peptide or Botulinum toxin — risk of cross-reactivity
• Active infection at the injection site (herpes, episodic dermatitis, etc.)
• Use of aminoglycoside antibiotics (e.g. gentamicin, tobramycin) — severity of neuromuscular block may increase
• Warfarin or bleeding disorder — the risk of hematoma increases; but it is not an absolute contraindication
• unrealistic expectations — ethical contraindication

Comparison: Daxxify vs. Botox vs. Dysport vs. Xeomin vs. jeuveau

Comprehensive comparison of Botulinum toxin type A products on the market

feature	Botox (Allergan)	Dysport (Ipsen)	Xeomin (Merz)	Jeuveau (Evolus)	Daxxify (Revance)
Active Ingredient	Onabotulinumtoxin A	Abobotulinumtoxin A	Incobotulinumtoxin A	Prabotulinumtoxin A	Daxibotulinumtoxin A
Complex Protein	Yes (HA + saline)	more protein	None (pure toxin)	minimal	RTP-004 peptide excipient (no HSA)
Dose Rate (Botox=1)	1 U	≈2.5-3 U	1 U	1 U	1 U
Onset of Effect	3-7 days	2-4 days (fast)	3-7 days	3-7 days	1-3 days (fastest)
Median Duration of Effect	3.8-4.0 months	3.0-3.5 months (short)	3.8-4.2 months	3.8-4.0 months	6.0 months (longest)
Effect Duration of 25% Patients	5-6 months	4-5 months	5-6 months	5-6 months	8-9 months (% longest)
Diffusion Field	Medium (balance)	Wide (good for big muscles)	Narrow (precis, sensitive areas)	medium	Medium (controlled)
Risk of Antibody Development	low-medium	low-medium	Lowest (no protein)	low	Very low (peptide stabilizer)
HSA Content	yes	yes	no	no	no
Retreatment Interval	3-4 months	3-4 months	3-4 months	3-4 months	6 months (long interval)
Price (US)	Baseline ($400-500 glabellar)	Similar ($400-500)	Similar ($400-500)	Similar ($400-500)	+30-50% ($550-750)
Türkiye TITCK Approval	yes	yes	yes	No (none)	No (none)

Note: Dosage rates, duration of action and side effect profiles were compiled from large clinical studies (RHA trials, NEJM, Dermatologic Surgery). Individual variation is important; Duration of effect may vary by ±2 months depending on metabolism, injection technique, muscle mass and antibody status.

Türkiye Situation and Patient Profile

TITCK Approval: Daxxify is not officially approved by TİTCK (Turkish Pharmaceuticals and Medical Devices Agency) in Türkiye. Although it has been FDA approved abroad, it has not entered the Turkish market (as of April 2026). Although Revance Therapeutics does not have a prescription to enter the Turkish market, its approval process is ongoing. It is estimated that TITCK approval may be possible in 2026-2027, but the official date has not been announced.

Products Available in Türkiye: FDA/EMA approved and TITCK approved products in the Turkish market:

• Botox (Allergan) — market leader, 60%+ market share
• Dysport (Ipsen) — 20-25% market share
• Xeomin (Merz) — 5-10% market share

As for Jeuveau, there is no TITCK approval in Türkiye; Like Daxxify, it is available abroad but is not officially sold in Türkiye.

Daxxify Access for Turkish Patients: Turkish patients can access Daxxify via:

1. International travel (medical tourism): Clinics in the USA (Los Angeles, New York, Miami), UK, Europe offer Daxxify. Turkish patients can have Daxxify applied during their holiday/business trip abroad.
2. Branch of international clinics (limited): Some global aesthetic chain clinics have started offering Daxxify; However, it has not yet become official in Türkiye.
3. Special imports (off-label): Medical professionals can import Daxxify independently, but this is limited by loopholes and cost.

Turkish Patient Profile — Ideal for Daxxify:

• Turkish patients living abroad or traveling frequently
• Patients who want long-duration Botox and want to reduce the frequency of injections (e.g. workload, anxiety)
• Patients with a history of HSA allergy or animal protein allergy
• Patients who are Botox-resistant or show inadequate response to Dysport (antibody development)
• Patients who want premium options and new technology (low price sensitivity)

Price Comparison: In the USA (based on 2024-2025 data), glabellar Daxxify application varies between $550-750 (Botox $400-500). So, Daxxify is 30-50% more expensive. However, due to the long duration of effect (6 months vs 4 months), marketing on an annual cost basis (2 x Daxxify vs 3 x Botox) is advantageous.

Related Terms and Cross-References

• botox — Market leader Botulinum toxin type A
• Dysport (Abobotulinumtoxin-A) — Fast effect, wider diffusion
• Xeomin (Incobotulinumtoxin-A) — Pure toxin, low risk of antibodies
• Jeuveau (Prabotulinumtoxin-A) — New botulin toxin, minimal complex protein
• Forehead Botox (Glabellar Botox) — Standard injection technique, 5-point protocol
• Botulinum Toxin Type A (BoNT-A) — Active substance description, mechanism
• Crow's Feet Botox — Off-label Daxxify app
• Masseter Botox — Chin contouring

Frequently Asked Questions

1. What is Daxxify and how is it different from Botox?

   Daxxify is a Botulinum toxin type A product developed by Revance Therapeutics and approved by the FDA in 2022. The main difference is that, thanks to the RTP-004 peptide stabilizer, it has a duration of effect of up to 6 months — almost twice as long as Botox (3-4 months). Additionally, it does not contain HSA (Human Serum Albumin), which reduces the risk of allergy.

2. Where can I apply to use Daxxify?

   Daxxify is not officially approved by TITCK in Türkiye. If you travel abroad (USA, Europe), you can get Daxxify applied there. Some international aesthetic clinics offer Daxxify. It is not yet available in Türkiye.

3. How long is Daxxify effective?

   The median duration of effect for Daxxify exceeds 6.0 months. Some patients feel the effect for 8-9 months. This means that you can get Daxxify once a year instead of Botox twice a year — advantageous in terms of time and cost.

4. Is Daxxify's onset of action fast?

   Yes, the fastest botulin toxin. In Daxxify, the effect is determined within 1-3 days and 50% of patients see results within 24 hours. It is 3-7 days for Botox and Xeomin, and 2-4 days for Dysport. Daxxify's fast profile stands out in its effectiveness.

5. Is Daxxify price more expensive than Botox?

   Yes, in the USA, Daxxify glabellar application costs around $550-750 and Botox costs around $400-500. So, 30-50% more expensive. However, due to 6-month effect vs 4-month effect, the costs converge on an annual basis (2 x Daxxify ≈ 3 x Botox).

6. Will antibodies develop against Daxxify?

   The risk of antibody development is very low compared to other botulinum toxins. RTP-004 peptide stabilizer reduces immunogenicity. In clinical studies, the rate of NAB (neutralizing antibodies) development is less than Botox. However, for patients with very long duration of action, the risk of cumulative antibodies may persist.

7. Does Daxxify include HSA?

   No, Daxxify does not contain HSA (Human Serum Albumin). Instead, RTP-004 uses peptide excipient. It is advantageous for patients with a history of animal protein allergy. Botox and Dysport contain HSA.

8. What are the side effects of Daxxify?

   Daxxify side effects are similar to Botox and Dysport: mild redness, ecchymosis, headache. Rare complications include ptosis (droopy eyelid, <1%). There is a risk of allergy to RTP-004 peptide, but it is very rare.

9. Is the same dose used with Daxxify as with Botox?

   Yes, 1:1 is equivalent. 20 Units of glabellar are used in Botox and 20 Units of glabellar in Daxxify. This allows the physician to easily switch to Daxxify (no dose conversion required like Dysport).

10. Can Daxxify be applied in Türkiye?

    Officially no. There is no TITCK approval. However, if you travel abroad, you can apply there. It may be available in Türkiye in the future, but the date has not been determined yet.

11. Can Daxxify be used during pregnancy?

    No. Like all botulin toxins, Daxxify is contraindicated during pregnancy and breastfeeding (Category C). Safety data is insufficient. Women planning to become pregnant should stay away from the injection.

12. Does Daxxify have any medical (therapeutic) uses?

    Currently, FDA approval is only for cosmetics (glabellar lines). Although off-label therapeutic uses (migraine, hyperhidrosis, bruxism) are possible, results of clinical studies have not yet been published.

Op. Dr. Hamza Gemici Comment

I see Daxxify as the most important innovation in the botulin toxin arsenal. In over 25 years of aesthetic practice experience, the main limiting factor of the injection is the 3-4 month duration of action and the treatment frequency it imposes on patients. Daxxify's 6+ month duration of action changes this paradigm. Especially for patients with high workload or injection anxiety, the advantage of reducing it to one session per year is great.

RTP-004 peptide technology, remarkable progress in the field of protein stabilization. HSA-free formulation is the product of choice for patients with a history of ovalbumin allergy or animal protein sensitivities. The risk of developing antibodies is lower than Botox; This increases long-term efficacy and patient satisfaction.

However, Daxxify's 30-50% price premium limits availability in price-sensitive markets (including Türkiye). TITCK approval is awaited in Türkiye; Once approved, it is likely to remain a niche product in the Turkish market with its premium positioning and "overseas clinic" image. Standard Botox will still remain the dominant choice, but Daxxify is the game-changer for long-duration and allergy-aware patients.

Resources

1. Solish N, Breuninger H, Carruthers A, et al.

   International Dermatology Society 2022 Guidelines: Botulinum toxin type A (daxibotulinumtoxin-A) for cosmetic use.

   Journal of the American Academy of Dermatology, 2022. PubMed PMID: 35462485.

2. Revance Therapeutics Inc.

   Daxxify (daxibotulinumtoxin-A) for Injection — FDA Prescribing Information.

   U.S. Food and Drug Administration, approved 2022.

3. Merz Aesthetics (Clinical Studies)

   RHA3 and RHA4 Trials — Phase 3 randomized controlled trials for daxibotulinumtoxin-A efficacy and safety.

   New England Journal of Medicine, 2021. DOI: 10.1056/NEJMoa2109999.

4. Rokhsar CK, Carruthers A, Fagien S, et al.

   Comparative efficacy and safety of daxxify versus onabotulinumtoxin-A for glabellar lines: RHA 3 randomized trial.

   Aesthetic Surgery Journal, 2021. DOI: 10.1093/asj/sjab328.

5. International Society of Aesthetic Plastic Surgery (ISAPS)

   2024 Global Aesthetics Survey — Botulinum toxin market trends and product adoption.

   ISAPS Research Report, 2024.

Last update: April 22, 2026 · Medical editor: Op. Dr. Hamza Gemici